Category Archives: Analgesia

Wearable medical devices are yielding increasingly important insights into health. Rosalind Picard, Sc.D., professor of Media Arts and Sciences at MIT, discussed the applications of one such device, wearable wrist sensors that measure electrical changes in the skin, in an informative plenary lecture we attended at the American Pain Society’s 36th annual meeting in Pittsburgh,Read more

The most prevalent gauge of efficacy in the study of fibromyalgia drugs is — no surprise here — pain relief. But analgesic effect alone is not a sufficient measure in the eyes of the FDA, which seeks evidence of overall benefit and improvement in patient function when evaluating treatments for a condition commonly associated withRead more

DURHAM, N.C., May 17, 2017 — Scott Millard, Premier Research’s head of analgesia strategic development, will speak on fibromyalgia clinical trials during a Town Hall Talk at the American Pain Society’s Annual Scientific Meeting, May 17-20 in Pittsburgh. Mr. Millard will present Operationalizing Clinical Trials in Fibromyalgia on Thursday, May 18, starting at 9:40 a.m.Read more

The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) is a major group providing guidance for design considerations of acute pain clinical trials. IMMPACT is made up of a team consisting of some of the most respected researchers and clinicians in the field of pain medicine. As of 2016, IMMPACT recommends these ten best practicesRead more

Short-duration acute pain management trials involve a variety of complex factors that must be taken into account for successfully evaluating the safety and efficacy of a new analgesic product. These five considerations are key. 1. Choosing the Right Model There are a number of established pain models for clinical research, each with its own type, intensity,Read more

When it comes to analgesic drug development, it’s important to optimize design of early phase trials. The main objectives of studies at this stage are to: Explore a range of doses Obtain data on onset, peak effect, and duration Assess relative efficacy in comparison to established analgesics To accurately evaluate their product, sponsors need toRead more

Central nervous system (CNS) disorders are a diverse group of conditions that include psychiatric, neurological and substance abuse disorders. Unfortunately for patients, treatment options for CNS disorders are often limited (or non-existent). To make matters worse, comparatively few CNS drugs are in the development pipeline. What aspects of CNS disorders contribute to lagging drug development? Read on toRead more

DURHAM, N.C., April 12, 2016 — Study of acute pain drugs can benefit greatly from preclinical research. Premier Research will explain why and how in a webinar on Tuesday, April 12. The hour-long event will begin at 11 a.m. EDT / 4 p.m. BST / 5 p.m. CEST. Evaluating a medication for acute pain typically startsRead more

Phone Us Now
Email Us Now